Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Price Performance

NERV stock opened at $1.76 on Friday. The stock has a market capitalization of $12.31 million, a PE ratio of -4.00 and a beta of -0.09. The company has a 50 day moving average price of $1.63 and a 200 day moving average price of $2.04. Minerva Neurosciences has a fifty-two week low of $1.15 and a fifty-two week high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49. As a group, equities analysts expect that Minerva Neurosciences will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Minerva Neurosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in NERV. Apella Capital LLC bought a new stake in shares of Minerva Neurosciences in the first quarter valued at about $35,000. Citadel Advisors LLC boosted its holdings in Minerva Neurosciences by 49.5% during the fourth quarter. Citadel Advisors LLC now owns 25,764 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 8,525 shares during the last quarter. Finally, Northern Trust Corp grew its position in Minerva Neurosciences by 60.0% in the fourth quarter. Northern Trust Corp now owns 36,878 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 13,829 shares in the last quarter. 34.56% of the stock is currently owned by institutional investors and hedge funds.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.